Skip to main content

Table 2 Comparision of laboratory tests and weight between the two groups before and after treatment

From: A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy

 

Pretreatment

Post treatment

Week 0

Week 16

Parametes

Gliclazide

Vildagliptin

P

Gliclazide

Vildagliptin

P

Fasting TC (mg/dL)

195.2 ± 26.9

190.1 ± 35.8

0.636

194.0 ± 32.2

192.6 ± 36.4

0.904

Postprandial TC (mg/dL)

193.1 ± 25.9

186.8 ± 34.8

0.544

191.3 ± 32.9

192.8 ± 37.2

0.899

Fasting HDL (mg/dL)

51.1 ± 10.0

60.0 ± 18.9

0.086

51.3 ± 10.4

62.3 ± 15.6

0.021

Postprandial HDL (mg/dL)

50.2 ± 9.3

59.3 ± 17.9

0.150

51.1 ± 10.8

62.9 ± 16.0

0.015

Fasting Triglycerides (mg/dL)

177.3 ± 87.3

197.1 ± 116.0

0.567

205.1 ± 100.3

190.7 ± 106.2

0.635

Postprandial Triglycerides (mg/dL)

207.9 ± 89.3

218,4 ± 110.0

0.849

221.8 ± 90.1

197.4 ± 86.1

0.342

Fasting glucose (mg/dL)

179 ± 57.9

168.7 ± 31.3

0.475

131.7 ± 30.5

132.9 ± 24.8

0.896

Post prandial glucose (mg/dL)

242.83 ± 71.7

241.4 ± 69.5

0.825

191.2 ± 54.8

194.5 ± 47.4

0.847

A1c (%)

9.2 ± 1.2

8.6 ± 0.9

0.109

6.9 ± 1.1

6.9 ± 0.8

0.800

Weight

82.0 ± 14.6

71.4 ± 8.0

0.012

83.4 ± 14.8

71.0 ± 8.1

0.005

Weight Change (kg)

-

-

-

+1.4 ± 3.0

−0.3 ± 2.0

0.048

  1. Data are means ± SD. TC total cholesterol, HDL high dense lipoprotein